ACAL Energy

Dr S B Cha - Chief Executive Officer

Dr S B Cha joined ACAL Energy as CEO in August 2007. SB gained his first and Masters degree in Chemical Engineering at Colorado School Mines in the USA, followed by a PhD in Statistical Thermodynamics from Imperial College, London. Sb also has an MBA from the University of Chicago. During his early career, Sb worked as a Research Engineer for IUPAC in London and as Project Manager for Texaco in the US. Following his MBA, Sb joined Boston Consulting Group as a Management Consultant. Sb then moved to Philips Components in California, initially as VP Customer Development and latterly as VP Strategic Marketing & Business Development. Most recently Sb worked with CDT Limited, in Cambridge, UK as Vice President, Commercial. He had overall responsibility for CDT's Marketing, sales and business development activities.

Dr Andrew Creeth - Chief Technology Officer

Andrew has extensive experience of the industry based R&D processes built at one of the world's leading blue chip companies. He has a strong inventive record with 17 patents. Andrew stems from a sound science base, with depth of knowledge, 11 publications, and has led teams which delivered the technology for market launches. He is an all round strategic Technical Director particularly adept at managing complex teams to deliver technology, through strategic alliance. He is the inventor of the ACAL Energy technology; transferring proven knowledge from other industries into this exciting area.

Amanda Lyne - Commercial Director

Amanda has a broad based commercial experience, built in one the UK's leading chemical companies and a number of technology start ups. Her previous roles have included Global Business Manager for businesses with over £250M turnover as well as strategic marketing, business development and technology licensing. She has extensive project management experience and a proven track record in delivering commercial collaborations and R&D agreements. She has practical experience of creating value out of innovative science and leading businesses through private funding and AIM flotation.

Board of Directors:

Bob Pettigrew - Non Executive Chairman

Mr Pettigrew has more than 20 years experience in the development of emerging businesses having been a director and investor of a number of growth oriented companies over this period. In 1986 he co-founded Generics which has grown rapidly to become one of the leading technology consulting and investment groups and was key member of the team that took the company public in December 2000. He also was involved in developing Generics investment activities in early stage technology ventures and was a director of the group investment company Generics Asset Management. He retired from Generics at the end of 2002 to pursue independent investment activities. He is an investor director on the board of a number of technology companies including Sphere Medical, BioWisdom, Zinwave, Oxonica, Timberpost and Digital Health Care. He was Chairman of Voxar Ltd and managed its $50m trade sale in Sept 2004. He is a member of the advisory boards of Antenova, the Synergy Fund as well as being a non executive board member of two Venture Capital Trusts listed on the London Stock Exchange.

David Fyfe - Non Executive Director

Dr David Fyfe, a 30-year veteran of the global chemical and engineering industries, most recently as Chairman and CEO of CDT Ltd. He is experienced in driving commercial businesses and has extensive expertise in negotiating joint ventures, acquisitions and partnerships. Previous positions include senior executive roles in companies on both sides of the Atlantic, including ICI and BF Goodrich. Dr Fyfe spent three years as CEO of Harris Speciality Chemicals (HSC), headquartered in Jacksonville, FL, USA. This $250 million turnover company had 900 employees, seven manufacturing plants in the U.S., and 11 locations in Europe and Asia. At HSC, Fyfe led a very successful turnaround and subsequent sale of the company to SKW - part of Germany's Viag Group - on behalf of Kelso & Company, one of the principal investors in CDT. With a BA and MA from Cambridge University in Natural Sciences and a PhD for a dissertation in electrochemistry, Fyfe has chaired and taken part in a number of industry focused government bodies. He has chaired the UK Chemical Industries Association Business and Trade Board, was a member of the UK Department of Trade and Industry's deregulation taskforce for the chemical and pharmaceutical industries and Vice Chairman of the UK CBI Northern Region.

James Wilkie - Investor Representative Non Executive Director

Dr James Wilkie joined the Board in April 2007. Formerly Development Director with Johnson Matthey Fuel Cells, he has many years experience in energy market analysis and commercialisation of sustainable technologies. Other former positions include : Managing Director of Morgan Crucible's R&D activities (including Fuel Cells), Vice President Technology of Shell Solar photovoltaics business; co-founder of Shell International Renewables; advisor to Shell Hydrogen and scenario planning and strategy advice to the Royal Dutch/Shell Managing Directors. He has also been a member of the advisory board for the UK Centre for Renewable Energy Systems & Technology (CREST) for many years, is a member of the Grove Fuel Cell Advisory Committee and holds both an MBA and Chartered Engineer status.

Dan Dajie - Non Executive Director

Dan has been NXD with ACAL Energy since 2004, and used his extensive experience of the fuel industry to support the development of the company. Dan, who is based on the US East Coast, was one of the founding directors of Polyfuel Plc, and provides consultancy advice and technical due diligence for investors in early stage technology companies across the USA, particularly in the novel renewable energy sectors. Over the last two years he has worked with and seen over 42 fuel cell companies.